Cyclin D2 plays an important role in regulation of hematopoietic cell proliferation by cytokines and is implicated in oncogenesis of various hematopoietic malignancies. However, mechanisms regulating cyclin D2 stability and its expression level have remained to be known. Here, we demonstrate that interleukin-3 signaling stabilizes cyclin D2 by inhibition of glycogen synthase kinase-3b (GSK3b) through Janus kinase2-dependent activation of phosphatidylinositol 3 0 -kinase (PI3K)/Akt signaling pathway in hematopoietic 32Dcl3 cells. On the other hand, osmotic stress was shown to induce a rapid proteasomal degradation of cyclin D2, which was mediated by activation of p38. GSK3b and p38 was demonstrated to phosphorylate cyclin D2 on Thr280 in vitro, while a cyclin D2 mutant with this residue substituted with Ala was found to be resistant to ubiquitination and proteasome-dependent degradation in 32Dcl3 cells. Inhibition of the PI3K pathway or induction of osmotic stress also caused a rapid proteasomal degradation of cyclin D2 in primary leukemic or myeloma cells. These results indicate that cyclin D2 expression in normal and malignant hematopoietic cells is regulated by ubiquitin/proteasome-dependent degradation that is triggered by Thr280 phosphorylation by GSK3b or p38, which is induced by inhibition of the PI3K pathway or by osmotic stress, respectively.
Introduction D-type cyclins (cyclins D1, D2 and D3) are major integral mediators linking the extracellular signaling environment with cell-cycle progression (Sherr and Roberts, 1999; Murray, 2004) . They function as key sensors for mitogenic growth factors, and their expression levels appear to be rate limiting for cell-cycle G1 progression. D-type cyclins assemble with either cdk4 or cdk6 and trigger G1 progression mainly through inactivation of the retinoblastoma protein pRB and related family members. Each D-type cyclin may have distinctive functions as they are often expressed mutually exclusively in different cell types and different embryonic stages. However, there is functional redundancy among these D-type cyclins, which share a high degree of amino-acid homology with 50-60% identity throughout the coding region. Indeed, mice deficient for individual D-type cyclins show only limited tissuespecific abnormalities (Kozar and Sicinski, 2005) . Furthermore, cyclin D2 could substitute the function of cyclin D1 in mouse development (Carthon et al., 2005) . Because the functions of three D-type cyclins are interchangeable, differences in mechanism regulating expression of each D-type cyclin should be very important to determine the roles each member plays in regulation of cell-cycle progression of various types of cells.
The proliferation and apoptosis of hematopoietic progenitor cells are regulated by hematopoietic cytokines, such as interleukin-3 (IL-3), erythropoietin and thrombopoietin. The receptors for hematopoietic cytokines mainly couple with a member of the Janus kinase (JAK) family of tyrosine kinases, Jak2, to activate a similar set of signal transduction pathways, including those involving signal transducer and activator of transcription-5 (STAT5), Ras and phosphatidylinositol 3 0 -kinase (PI3K) (Ihle, 1995) . A serine/threonine kinase, Akt, is activated downstream of PI3K to regulate various cellular processes such as apoptosis, cell-cycle progression, transcriptional regulation and glucose uptake by phosphorylating various signaling molecules, including Bad, p21, p27, the forkhead family transcription factors and glycogen synthase kinase-3b (GSK3b) (Brazil et al., 2004) . GSK3b, a serine/threonine kinase, is normally active in cells and is primarily regulated through inhibitory phosphorylation by Akt and other serine/threonine kinases (Jope and Johnson, 2004) . Recent studies have revealed that GSK3b is a key regulator of numerous signaling pathways and is involved in a wide range of cellular processes, ranging from glycogen metabolism to cell-cycle regulation and proliferation. In murine IL-3-dependent hematopoietic progenitor cell lines, IL-3 has been shown to induce cyclin D2 mRNA and protein expression, mainly through activation of the PI3K-dependent pathway, to promote G1 cell-cycle progression (Ando et al., 1993; Parada et al., 2001; Fox et al., 2005) .
D-type cyclins are implicated in oncogenesis, because these key regulators for G1 cell-cycle progression are overexpressed in various neoplasms and contribute to cellular transformation, when overexpressed or mutated (Malumbres and Barbacid, 2001; Deshpande et al., 2005) . In accordance with its important role in hematopoietic cells, overexpression of cyclin D2 has been reported mostly in various hematopoietic malignancies as well as in germ cell tumors. Although the mechanisms for cyclin D2 overexpression in most of these tumors remain to be known, very recent studies showed the aberrant expression of the cyclin D2 gene located at chromosome 12p13 through chromosomal translocations, t(12;14) or t(7;12), in T-cell acute lymphoblastic leukemia (ALL) (Clappier et al., 2006; Karrman et al., 2006) . It was also reported that breakpoint cluster region/abelson kinase (BCR/ABL), the fusion tyrosine kinase causing chronic myelogenous leukemia and Ph þ ALL, induces cyclin D2 overexpression, which was found to play a crucial role in proliferation and transformation of hematopoietic cells by BCR/ABL (Deininger et al., 2001; Parada et al., 2001; Jena et al., 2002) . Thus, deregulated expression of cyclin D2 may play an important role in pathogenesis of hematopoietic malignancies.
Expression of D-type cyclins is regulated mainly at the transcriptional level (Sherr and Roberts, 1999; Murray, 2004) . For instance, expression of the cyclin D2 gene is upregulated mainly by activation of the PI3K pathway as well as by STAT5 and c-Myc (Chiles, 2004) . Recent studies have demonstrated, however, that expression of D-type cyclins is also regulated at posttranscriptional levels. Most importantly, Diehl et al. (1997 Diehl et al. ( , 1998 have demonstrated that cyclin D1 expression is regulated by the ubiquitin/proteasome-dependent degradation, which is triggered by phosphorylation of Thr286 of cyclin D1 by GSK3b. On the other hand, Casanovas et al. (2000) showed that the p38 kinase activated by osmotic stress also phosphorylates Thr286 of cyclin D1 to trigger its ubiquitin/proteasomedependent degradation. Recent reports further showed that Thr283 in cyclin D3, corresponding to Thr286 in cyclin D1, was also targeted by GSK3b or p38 for the ubiquitin/proteasome-dependent degradation (Casanovas et al., 2004; Naderi et al., 2004) . Although these observations suggest the common mechanisms for post-translational regulation, D-type cyclins are also regulated in different manners at the post-translational level. For instance, DNA damage causes specific degradation of cyclin D1, but not cyclin D2 or D3 (Agami and Bernards, 2000) . Moreover, although retinoic acid upregulates the expression of cyclin D2, it downregulates expression of cyclin D1 in a manner dependent on Thr286 and GSK3b or that of D3 in a manner independent of Thr283 and GSK3b (Ma et al., 2005) . In this regard, it is also notable that the role of GSK3b in phosphorylation of cyclin D1 or D3 has recently been challenged (Casanovas et al., 2004; Okabe et al., 2006; Yang et al., 2006) . In contrast to cyclins D1 and D3, strikingly little is known about the posttranslational regulation of cyclin D2.
In this study, we examine the mechanisms regulating cyclin D2 stability in the IL-3-dependent hematopoietic progenitor model cell line 32Dcl3 as well as in primary cells from patients with hematopoietic malignancies. The present study reveals that GSK3b or p38 phosphorylates cyclin D2 on Thr280, corresponding to Thr286 in cyclin D1, to regulate its ubiquitin/proteasomedependent degradation.
Results
The PI3K/Akt/GSK3b pathway plays a role in regulation of cyclin D2 expression through proteasomal degradation in IL-3-dependent cells Expression levels of D-type cyclins are regulated by intracellular signaling mechanisms activated by extracellular stimuli that regulate cell-cycle progression. To explore the signaling mechanisms that regulate cyclin D2 expression in hematopoietic cells by cytokine stimulation, we examined cyclin D2 expression in the IL-3-dependent hematopoietic progenitor model cell line 32Dcl3. Previous studies have shown that cyclins D2 and D3, but not D1, are expressed in this cell line (Ando et al., 1993; Kato and Sherr, 1993; Jena et al., 2002) . It has been further demonstrated IL-3 significantly increases the expression levels of cyclin D2 mRNA and protein but not those of cyclin D3 in this cell line (Ando et al., 1993) . As shown in Figure 1a , IL-3 stimulation of IL-3-starved 32Dcl3 cells induced expression of cyclin D2 with concurrent phosphorylation of pRb, which was observed as early as 3 h after stimulation and increased gradually thereafter. Pretreatment with Jak inhibitor I (Jak-I) (Lucet et al., 2006) , which inhibits the Jak2 kinase activated by IL-3, abrogated IL-3-induced cyclin D2 expression and pRb phosphorylation. Because Jak2 plays a crucial role in activation of various downstream signaling pathways, including the STAT5, mitogenactivated protein kinase kinase/extracellular signalregulated kinase (MEK/Erk) and PI3K/Akt pathways, from the IL-3 receptor (Ihle, 1995) , we also examined the effects of inhibition of the PI3K/Akt and MEK/Erk pathways separately. The IL-3-induced cyclin D2 expression was drastically inhibited by pretreatment with the PI3K inhibitor LY294002 but not by the MEK inhibitor PD98059. Thus, Jak2-mediated activation of the PI3K pathway by IL-3 plays an essential role in induction of cyclin D2 expression. This is in agreement with previous reports that demonstrated that PI3K pathway plays an essential role in transcriptional activation of the cyclin D2 gene (Chiles, 2004) . Recent studies on cyclin D1 and cyclin D3, however, have shown that expression of these D-type cyclins are regulated also at post-transcriptional levels, most significantly at the post-translational level (Diehl et al., 1997 (Diehl et al., , 1998 Casanovas et al., 2000 Casanovas et al., , 2004 Naderi et al., 2004) . We thus examined the possible involvement of post-translational mechanisms in cytokine regulation of cyclin D2 expression in hematopoietic cells.
As shown in Figure 1b , treatment of 32Dcl3 cells with the protein synthesis inhibitor cycloheximide (CHX) induced a rapid decline in level of cyclin D2 expression. Thus, similar to cyclin D1 and cyclin D3, cyclin D2 was shown to be labile and undergoing a rapid turnover. When cells were pretreated with Jak-I, CHX induced a more rapid decline in cyclin D2 level than when CHX was used alone (Figure 1b) , thus suggesting that the signaling pathways activated downstream of Jak2 by the IL-3 receptor may regulate cyclin D2 expression not only by activating its gene expression but also by stabilizing cyclin D2 protein. To explore the possible involvement of PI3K pathway in this regulatory mechanism, we pretreated cells with LY294002 before CHX treatment. As shown in Figure 1c , LY294002 pretreatment significantly facilitated cyclin D2 degradation, while pretreatment with PD98056 did not show any significant effect (negative data not shown). To explore the downstream effector molecules involved in PI3K-mediated regulation of cyclin D2 stability, we examined the effect of SB216763, a specific inhibitor of GSK3b that is phosphorylated and inactivated by the Akt kinase activated by PI3K. Pretreatment of cells with SB216763 abrogated the ability of LY294002 to facilitate cyclin D2 instability (Figure 1c , bottom panels), thus suggesting that inhibition of GSK3b may be (a) IL-3-dependent 32Dcl3 cells were washed out from IL-3 for 16 h and then left untreated as control or preincubated for 30 min with 1 mM Jak-I, 50 mM LY294002 or 50 mM PD98059, as indicated. Cells were then stimulated with 100 U/ml murine IL-3 for indicated times and lysed. Cell lysates were subjected to western blot analysis with anti-cyclin D2, followed by reprobing with antibodies against phospho-pRb, pRb and a-tubulin, as indicated. Relative expression levels of cyclin D2, determined by densitometric analysis of the anti-cyclin D2 blot, are shown. (b) 32Dcl3 cells were pretreated for 30 min with 1 mM Jak-I or left untreated as control, as indicated. Cells were then treated with 10 mg/ml CHX and lysed after indicated times. Cell lysates were subjected to western blot analysis with anti-cyclin D2 followed by reprobing with anti-a-tubulin, as indicated. (c) 32Dcl3 cells were left untreated as control, treated with 50 mM LY294002 for 60 min (LY), or pretreated with 20 mM SB216763 for 30 min and then additionally treated with 50 mM LY294002 for 60 min (SB þ LY) before addition of 10 mg/ml CHX. Cells were lysed after indicated times and analysed as described above. (d) 32Dcl3 cells were transiently transfected with 40 mg of pUSE-myr-Akt (Akt-myr) or with an empty plasmid (control) along with 20 mg of pcDNA3-cyclin D2. After overnight starvation in medium without IL-3, cells were treated with 10 mg/ml CHX and lysed after indicated times. Cell lysates were subjected to western blot analysis with anti-cyclin D2 followed by reprobing with antibodies against phospho-Akt and a-tubulin, as indicated. (e) 32Dcl3 cells were treated for 3 h with 5 mM MG132 and 50 mM LY294002, as indicated. Cell lysates were analysed as described above. (f) 32Dcl3 cells were treated with 5 mM MG132 for indicated times and lysed. Cyclin D2 was then immunoprecipitated and subjected to western blot analysis with anti-ubiquitin, followed by reprobing with anti-cyclin D2 and anti-phospho-cyclin D1, as indicated. CHX, cycloheximide; IL-3, interleukin-3; Jak, Janus kinase; PI3K/Akt/GSK3b, phosphatidylinositol 3 0 -kinase/Akt/glycogen synthase kinase-3b.
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A Kida et al responsible for cyclin D2 stabilization by activation of the PI3K/Akt pathway. As shown in Figure 1d , transient coexpression of a constitutively activated Akt mutant stabilized cyclin D2 and increased its expression level. On the other hand, treatment of 32Dcl3 cells with LY294002 decreased expression level of cyclin D2, which was mostly prevented by cotreatment with the proteasome inhibitor MG132 (Figure 1e ). These data suggest that the PI3K pathway-mediated stabilization plays a substantial role in regulation of cyclin D2 expression and that the proteasome-mediated degradation may be involved in this regulatory mechanism. To examine this possibility, we treated 32Dcl3 cells with MG132 for various times and examined cyclin D2 that was immunoprecipitated by a specific antibody. As shown in Figure 1f , MG132 increased the expression level of cyclin D2 in a time course-dependent manner. Furthermore, antiubiquitin blotting of anti-cyclin D2 immunoprecipitates suggested the appearance of polyubiquitinated cyclin D2 in MG132-treated 32Dcl3 cells ( Figure 1f , upper panel). These results strongly suggest that cyclin D2 expression is regulated through the ubiquitin-proteasome pathway. In this regard, phosphorylation of cyclin D1 on Thr286 has been shown to trigger degradation of cyclin D1 through the ubiquitinproteasome pathway (Diehl et al., 1997 (Diehl et al., , 1998 . Because Thr286 in cyclin D1 is conserved as Thr280 in cyclin D2, and the amino-acid sequences following these sites are also well conserved, we tried to examine the possible phosphorylation of cyclin D2 on Thr280 by using a Thr286 phospho-specific antibody raised against this region of human cyclin D1. Treatment of cells with MG132 significantly increased the reactivity of this antibody with cyclin D2, thus suggesting that cyclin D2 is phosphorylated on Thr280 and becomes very unstable unless the proteasomal activity is inhibited. These observations suggest that cyclin D2 is phosphorylated, most likely by GSK3b, on Thr280 and becomes susceptible to proteasomal degradation.
Cyclin D2 stability is regulated through phosphorylation at Thr280 by GSK3b
To explore the possibility that Thr280 in cyclin D2 is phosphorylated by GSK3b and plays a role in regulation of cyclin D2 expression, we generated 32Dcl3 cell lines stably overexpressing wild-type cyclin D2 (32D/ cyclin D2-Wt) or its mutant in which Thr280 is substituted by alanine (32D/cyclin D2-T280A). When Figure 2 Cyclin D2 expression is regulated through GSK3b-mediated phosphorylation of Thr280. (a) 32D/cyclin D2-Wt (WT) or 32D/cyclin D2-T280A (T280A) cells were treated with 10 mg/ml CHX for indicated times and lysed. Cell lysates were subjected to western blot analysis with anti-cyclin D2, followed by reprobing with anti-a-tubulin, as indicated. Relative expression levels of cyclin D2, determined by densitometric analysis, are shown. (b) 32D/cyclin D2-Wt (WT) or 32D/Cyclin D2-T280A (T280A) cells were treated with 5 mM MG132 for indicated times and lysed. Cyclin D2 was then immunoprecipitated and subjected to western blot analysis with anti-ubiquitin, followed by reprobing with anti-cyclin D2 and anti-phospho-cyclin D1, as indicated. An arrow indicates 34 kDa cyclin D2, while asterisks indicate polyubiquitinated cyclin D2. The heavy chain of immunoglobulin used for immunoprecipitation is indicated by a circle. (c) 32D/cyclin D2-Wt (WT) or 32D/cyclin D2-T280A (T280A) cells were starved of IL-3 for 16 h and then treated with or without 5 mM SB216763 and 20 mM LiCl for 4 h, as indicated. Cells were lysed and analysed as described above. (d) A recombinant GST protein (GST) as well as a GST fusion protein with wild-type cyclin D2 (WT) or with T280A mutant (T280A), as indicated, was incubated for in vitro kinase assay with recombinant GSK3b in the presence or absence of SB216763, as indicated. Samples were electrophoresed, transferred to a membrane and subjected to autoradiography (IVK), followed by immunoblot analysis with anti-GST (GST). CHX, cycloheximide; GSK3b, glycogen synthase kinase-3b; GST, glutathione S-transferase.
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A Kida et al these cells were treated with CHX, the decline in expression of the T280A mutant was significantly delayed as compared with that of wild-type cyclin D2 (Figure 2a ), thus suggesting that Thr280 plays a crucial role in regulation of cyclin D2 stability. Furthermore, treatment with MG132 significantly increased the expression level of wild-type cyclin D2 but not that of the T280A mutant (Figure 2b ). In 32D/cyclin D2-Wt cells but not in 32D/cyclin D2-T280A cells, MG132 also remarkably induced the appearance of presumably polyubiquitinated forms of cyclin D2, which were immunoprecipitated with anti-cyclin D2 and reacted with both anti-cyclin D2 and antiubiquitin. MG132 also induced the appearance of cyclin D2 that reacts with anti-phospho-Thr286 cyclin D1 antibody in 32D/cyclin D2-Wt cells but not in 32D/cyclin D2-T280A cells (Figure 2b , lower panel). These results strongly support the hypothesis that cyclin D2 is phosphorylated on Thr280 and becomes susceptible to proteasomal degradation. We next examined the possible involvement of GSK3b in Thr280 phosphorylation-mediated regulation of cyclin D2. As shown in Figure 2c , the expression level of wild-type cyclin D2 but not that of the T280A mutant was significantly decreased and became barely detectable when cell were starved of IL-3 for 16 h. Treatment of these cells with GSK3b inhibitors, SB216763 and LiCl, significantly increased the expression level of wildtype cyclin D2 but not that of the T280A mutant. The significant increase in exogenous wild-type cyclin D2 protein level in the absence of IL-3 is most likely due to its constitutive transcription from the cytomegalovirus promoter as well as the stabilization of the protein product by GSK3b inhibition. These results strongly implicate GSK3b in regulation of cyclin D2 expression through phosphorylation on Thr280.
We finally examined whether GSK3b phosphorylates cyclin D2 on Thr280 in vitro. As shown in Figure 2d , a glutathione S-transferase (GST) fusion protein containing the C-terminal portion of wild-type cyclin D2 but not that of T280A was phosphorylated in vitro by a recombinant GSK3b kinase, which was significantly, albeit not completely, inhibited by SB216763. Together, these data indicate that GSK3b phosphorylates cyclin D2 on Thr280 to trigger its degradation through the ubiquitin/proteasome pathway, which may be prevented by activation of the PI3K/Akt pathway by IL-3 stimulation.
Osmotic stress destabilizes cyclin D2 through activation of p38 Because expression levels of cyclin D1 and cyclin D3 have been shown to be downregulated in response to various cellular stresses, we next examined whether cyclin D2 is also downregulated in response to cellular stresses. As shown in Figure 3a , osmotic stress induced a rapid decline in cyclin D2 level in 32Dcl3 cells, which was accompanied by activation of p38. Furthermore, osmotic stress accelerated CHX-induced decline in cyclin D2 expression level (Figure 3b ), thus suggesting that osmotic stress destabilizes cyclin D2 to facilitate its degradation. The destabilization of cyclin D2 induced by osmotic stress was significantly inhibited by pretreatment with the p38 inhibitor SB203580 (Figure 3b) . It was further demonstrated that transient overexpression of p38 significantly facilitated the decline in expression of co-transfected cyclin D2 in response to osmotic stress (Figure 3c) . Finally, the decline in cyclin D2 level induced by osmotic stress in 32Dcl3 cells was mostly prevented by cotreatment with MG132 (Figure 3d ). Together, these results strongly suggest that osmotic stress triggers proteasome-mediated cyclin D2 degradation through activation of p38. Figure 3 Osmotic stress destabilizes cyclin D2 through activation of p38. (a) 32Dcl3 cells were treated with 100 mM NaCl for indicated times and lysed. Cell lysates were analysed by western blot analysis with anti-cyclin D2, followed by reprobing with anti-phospho-p38 and anti-a-tubulin, as indicated. Relative expression levels of cyclin D2, determined by densitometric analysis, are shown. (b) 32Dcl3 cells were preincubated for 30 min with or without 50 mM SB203580, as indicated. Cells were then treated with 10 mg/ml CHX in the presence or absence of 100 mM NaCl, as indicated, for indicated times. Cells were lysed and subjected to western blot analysis with anticyclin D2 followed by reprobing with anti-a-tubulin, as indicated. (c) 32Dcl3 cells were transfected with 40 mg of an empty vector (control) or pCMV-Flag-p38 (Flag-p38) along with 20 mg of pcDNA-Hismax-cyclin D2. After culturing for 24 h in IL-3-containing medium, cells were treated with 100 mM NaCl for indicated times. Cell lysates were prepared and analysed by western blot analysis with anti-cyclin D2, followed by reprobing with indicated antibodies. Only exogenously expressed tagged cyclin D2 is shown in top panels. (d) 32Dcl3 cells were preincubated with or without 5 mM MG132 for 15 min and then further incubated with or without 100 mM NaCl for 60 min, as indicated. Cells were lysed and analysed as described above. CHX, cycloheximide.
A Kida et al p38 physically associates with cyclin D2 and phosphorylates it on Thr280 to induce destabilization To examine the possible involvement of Thr280 phosphorylation in osmotic stress-induced cyclin D2 degradation, we analysed the effect of NaCl treatment on the T280A mutant. As shown in Figure 4a , the T280A mutant was much more stable than wild-type cyclin D2 after treatment with NaCl, thus suggesting that Thr280 is involved in destabilization of cyclin D2 induced by osmotic stress. To confirm the involvement of p38 in regulation of cyclin D2 stability, we first examine its possible physical interaction with cyclin D2 in cells. For this purpose, His-tagged cyclin D2 or T280A mutant was transiently expressed with Flagtagged p38 in 32Dcl3 cells. As demonstrated in Figure 4b , anti-cyclin D2 immunoblotting of anti-Flag immunoprecipitates showed that endogenous cyclin D2 as well as both wild-type and T280A mutant cyclin D2 expressed exogenously was co-immunoprecipitated specifically with Flag-p38. Consistent with this, anti-p38 immunoblotting of anti-cyclin D2 immunoprecipitates showed that Flag-p38 was co-immunoprecipitated with both wild-type and T280A mutant cyclin D2 expressed exogenously in 32Dcl3 cells (Figure 4c ). We then tried to examine whether p38 directly phosphorylates cyclin D2 in vitro at Thr280. As shown in Figure 4d , the GST fusion protein containing the C-terminal portion of wild-type cyclin D2 but not that of T280A was phosphorylated in vitro by a recombinant p38 kinase, which was completely inhibited by SB203580. Taken together, these results strongly suggest that p38 physically interacts with cyclin D2, is activated by osmotic stress, and phosphorylates cyclin D2 on Thr280 to trigger proteasome-mediated degradation of cyclin D2.
Expression of cyclin D2 in primary hematopoietic cells are also regulated at the post-translational level through the similar mechanisms Because cyclin D2 is implicated not only in regulation of normal hematopoiesis but also in pathogenesis for various hematopoietic malignancies, we finally examined cyclin D2 expression and its possible post-translational regulation in primary hematopoietic tumor cells.
Western blot analysis of cell lysates showed that cyclin D2 was expressed at various levels in primary acute myeloid leukemia (AML) and ALL cells (unpublished observation). In addition, myeloma cells in pleural fluid from a patient with multiple myeloma (MM) exhibited a high expression level of cyclin D2. We selected three samples, each from a patient with AML, ALL, MM, that expressed cyclin D2 at high levels, and examined the cells ex vivo to analyse the post-translational regulation of cyclin D2. As shown in Figure 5a , treatment with CHX revealed that cyclin D2 is unstable and, thus, undergoing a rapid turnover also in these hematopoietic tumor cells. Furthermore, LY294002 significantly decreased cyclin D2 expression, which was partly prevented by cotreatment with MG132 ( Figure 5b ). Treatment of these cells with GSK3b inhibitors, SB216763 and LiCl, slightly increased expression levels of cyclin D2, although the effects were not as conspicuous as those observed in factor-deprived 32Dcl3 cells (Figure 5b , right panels). These results suggest that activation of the PI3K pathway may play a Figure 4 p38 physically associates with cyclin D2 and phosphorylates it on Thr280 to induce its destabilization. (a) 32D/cyclin D2-Wt (WT) or 32D/cyclin D2-T280A (T280A) cells were treated with 100 mM NaCl for indicated times and lysed. Cell lysates were subjected to western blot analysis with anti-cyclin D2 followed by reprobing with anti-phospho-p38 and anti-a-tubulin, as indicated. Relative expression levels of cyclin D2, determined by densitometric analysis, are shown. (b and c) 32Dcl3 cells were transfected with 30 mg of pCMV-Flag-p38 (Flag-p38) and 30 mg of pcDNA4-Hismax-cyclin D2 (W) or pcDNA-Hismax-cyclin D2-T280A (M), as indicated, and cultured for 24 h. Transfected cells were lysed and subjected to immunoprecipitation with anti-Flag (b) or anti-cyclin D2 (c). Total cell lysates (TCL), corresponding to 5% of those used for immunoprecipitation, and immunoprecipitates were analysed by immunoblotting with indicated antibodies. Endogenous or tagged, exogenous cyclin D2 and p38 are indicated with circles or asterisks, respectively. (d) A recombinant GST protein (GST) as well as a GST fusion protein with wild-type cyclin D2 (WT) or with T280A mutant (T280A), as indicated, was incubated for in vitro kinase assay with recombinant p38 in the presence or absence of SB203580, as indicated. Samples were electrophoresed, transferred to a membrane and subjected to autoradiography (IVK), followed by immunoblot analysis with anti-GST (GST). GST, glutathione S-transferase.
role in preventing cyclin D2 from proteasomal degradation by inhibiting GSK3b also in these hematopoietic tumor cells. Expression levels of cyclin D2 in these cells were rapidly decreased by 100 mM NaCl, which was prevented at least partly by cotreatment with MG132 (Figure 5c ), thus indicating that osmotic stress triggers proteasomal degradation of cyclin D2 also in these hematopoietic tumor cells. Together, these results strongly suggest that cyclin D2 expression is regulated through the similar post-translational mechanisms in primary hematopoietic tumor cells and in cytokinedependent 32Dcl3 model cell line.
Discussion
The present study has revealed that IL-3 signaling stabilizes cyclin D2 against the ubiquitin/proteasomedependent degradation through Jak2-dependent activation of the PI3K/Akt pathway to inhibit GSK3b (Figure 1 ). Thr280 in cyclin D2, corresponding to Thr286 in cyclin D1, was shown to be phosphorylated in vitro by GSK3b and to be involved in induction of the ubiquitin/proteasome-dependent degradation of cyclin D2 in hematopoietic cells, because the T280A mutant lacking Thr280 was stabilized in cells without ubiquitinated and was not affected by inhibition of GSK3b (Figure 2 ). Furthermore, p38 was found to physically associate with cyclin D2 and to phosphorylate Thr280 to trigger the ubiquitin/proteasomal degradation of cyclin D2 in response to osmotic shock (Figures 3 and 4) . The proteasomal degradation of cyclin D2 was similarly induced in primary malignant hematopoietic cells when PI3K was inhibited or in response to osmotic shock ( Figure 5 ). In contrast to cyclins D1 and D3, very little has been known about the post-translational regulation of cyclin D2. Previously, Hu et al. (2002) reported that tumor necrosis factor (TNF) treatment of hematopoietic cell lines for 48 h downregulated expression of cyclin D2 as well as cyclin D3, which was inhibited by cotreatment with MG132. It was also demonstrated that treatment of these cells with TNF for 24 h increased cellular proteasome activity. Thus, it was suggested that cyclin D2 may undergo proteasome-dependent degradation in TNF-treated cells. More recently, Huang et al. (2007) reported that GSK3b is involved in downregulation of cyclin D2 expression induced by phosphatase and tensin homolog (PTEN), a major negative regulator of the PI3K/Akt pathway. The downregulation of cyclin D2 expression was mainly caused by the transcriptional repression mediated by the GSK3b/b-catenin/T-cell factor pathway in cooperation with cAMP response element-binding protein. However, cyclin D2 was significantly stabilized in PtenÀ/À murine embryonic fibroblasts (MEFs) as compared with that in Pten þ / þ MEFs, and LiCl treatment of wild-type MEFs as well as IL-3-dependent murine hematopoietic BAF3 cells significantly stabilized cyclin D2. Thus, it was suggested that GSK3b not only inhibited the cyclin D2 gene expression but also destabilized cyclin D2, although the effect of LiCl was observed after treatment of cells for 10 h and may not be dependent on inhibition of the GSK3b kinase activity alone. The present study has firmly demonstrated both proteasome-dependent cyclin D2 degradation and involvement of GSK3b in its destabilization, which were suggested by these previous studies, and further revealed the mechanisms involving GSK3b-mediated phosphorylation of Thr280 to trigger the ubiquitin/proteasome-dependent degradation. Diehl et al. (1997 Diehl et al. ( , 1998 previously demonstrated that GSK3b phosphorylates cyclin D1 on Thr286, which corresponds to Thr280 in cyclin D2, to induce its ubiquitination, nuclear export and proteasomal degradation. On the other hand, controversial results have Figure 5 Regulation of cyclin D2 expression by proteasomal degradation in primary leukemic and myeloma cells. (a) Primary tumor cells from a patient with AML, ALL or MM were treated with 10 mg/ml CHX for indicated times and lysed. Cells were lysed and subjected to western blot analysis with anti-cyclin D2 followed by reprobing with anti-a-tubulin, as indicated. Relative expression levels of cyclin D2, determined by densitometric analysis, are shown. (b) Primary tumor cells indicated were treated with or without 5 mM MG132, 50 mM LY294002, 5 mM SB216763 (SB) or 20 mM LiCl (Li), as indicated, for 4 h. Cells were lysed and analysed as described above. (c) Primary tumor cells indicated were treated with 100 mM NaCl for indicated times (left panels), or cells were pretreated with or without 5 mM MG132 for 15 min and then treated with or without 100 mM NaCl for 60 min, as indicated. Cells were lysed and analysed as described above. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CHX, cycloheximide; MM, multiple myeloma.
been reported for cyclin D3; Casanovas et al. (2004) demonstrated that p38 but not GSK3b phosphorylates cyclin D3 in vitro at Thr283, whereas Naderi et al. (2004) reported that GSK3b phosphorylated Thr283 to trigger proteasomal degradation of cyclin D3. Discordant results have also been reported for cyclin D1 in regard to the physiological significance of GSK3b in Thr286 phosphorylation-mediated degradation. For instance, Yang et al. (2006) reported that modulation of GSK3b activity influenced neither cyclin D1 phosphorylation on Thr286 nor its expression level in NIH3T3 cells. A discrepancy between the GSK3b activity and ubiquitindependent cyclin D1 degradation was also reported in Rat-1 fibroblasts expressing an activated H-Ras mutant (Shao et al., 2000) . Thus, it is conceivable that GSK3b-mediated cyclin D1 degradation may be important in selected cell types or in cells proliferating in response to certain stimuli. In this regard, it is notable that Erk and IkB kinase-a has also been reported to phosphorylate Thr286 in cyclin D1 to trigger its ubiquitin/proteasomedependent degradation (Kwak et al., 2005; Okabe et al., 2006) . In the present study, we demonstrated that GSK3b phosphorylates cyclin D2 in vitro at Thr280. Furthermore, by modulating activity of the PI3K/Akt pathway as well as GSK3b in IL-3-dependent 32Dcl3 cells or its subclone expressing the cyclin D2 T280A mutant, we showed that the PI3K/Akt pathwaymediated inactivation of GSK3b by IL-3 plays a role in stabilization of cyclin D2 against ubiquitin/proteasomedependent degradation. Further studies are, however, warranted to address the possibilities that Erk, IkB kinase-a, and other kinases may also be involved in regulation of cyclin D2 expression through phosphorylation of Thr280. As very recent studies have revealed that ubiquitination of cyclin D1 phosphorylated on Thr286 is mediated by the Skp1-Cul1-F box (SCF) or SCF-like complexes where FBX4 as well as aB crystallin or FBXW8 governs substrate specificity (Lin et al., 2006; Okabe et al., 2006) , future studies are also needed to identify the E3 ubiquitin ligase complexes involved in ubiquitination of cyclin D2 phosphorylated on Thr280.
The present study has revealed that osmotic stress induces a rapid proteasomal degradation of cyclin D2, which was enhanced by overexpression of p38 and was prevented at least partly by the p38 inhibitor SB203580 (Figure 3) . It was further revealed that p38 phosphorylates cyclin D2 in vitro at Thr280 and that the T280A mutant was not affected by osmotic stress (Figure 4) . These results thus indicate that p38 activated by osmotic stress phosphorylates cyclin D2 at Thr280 to trigger its proteasomal degradation, which is in harmony with previous studies on cyclins D1 and D3 (Casanovas et al., 2000 (Casanovas et al., , 2004 . It is notable that Casanovas et al. (2004) demonstrated that all the four isoforms of p38 (p38a, p38b, p38c and p38d) phosphorylate cyclin D3 in vitro at Thr283 corresponding to Thr280 in cyclin D2, which may explain that SB203580, the specific inhibitor for p38a and p38b, did not completely prevent the effect of osmotic stress on cyclin D2 (Figure 3b ). The present study further revealed that cyclin D2 physically associates with p38 in hematopoietic cells (Figure 4b and c) , although binding between endogenous proteins was not demonstrable most likely because of the difficulty in immunoprecipitation, particularly of p38. Although the region of cyclin D2 involved in association with p38 was not examined in the present study, it is interesting to note that a very recent study has shown that Erk binds cyclin D1 through a kinase docking site (D-domain) in cyclin D1 (Okabe et al., 2006) . Because the D-domain, a conserved motif involved in binding with the MAPK family members including p38, is conserved in all the D-type cyclins, it is tempting to speculate that this domain in cyclin D2 is involved in binding with p38. This possibility is currently under investigation in our laboratory. Recent studies have shown that p38 plays important roles in G1/S and G2/M cell-cycle checkpoint activation and in regulation of apoptosis in response to stress stimuli, including osmotic shock and DNA damage (Kyriakis and Avruch, 2001 ). For instance, we previously found that p38 is activated by treatment of hematopoietic tumor cells with the chemotherapeutic agent etoposide and plays a role in G2/M checkpoint activation through induction of persistent inhibitory phosphorylation of Cdc2 and, thereby, inhibits apoptosis (Kurosu et al., 2005) . Thus, we are currently also investigating the possibility that p38 activated by chemotherapeutic agents may play a role in G1/S checkpoint activation through inducing Thr280 phosphorylation-mediated degradation of cyclin D2 in hematopoietic cells.
In accordance with a previous report that the majority of primary AML samples expressed cyclin D2 or D3 but not cyclin D1 (Radosevic et al., 2001) , we found that most of the primary AML samples expressed cyclin D2 at various levels (data not shown). The cyclin D2 expression we found in primary myeloma cells is also consistent with previous studies implicating D-type cyclins including cyclin D2 in pathogenesis of MM (Bergsagel et al., 2005; Ely et al., 2005) . Importantly, we demonstrated that cyclin D2 is very labile in primary leukemic and myeloma cells and is regulated through the post-translational regulatory mechanisms that are similar to those in IL-3-dependent hematopoietic cells. Thus, considering along with a previous report that cyclin D2 mRNA did not correlate with its expression at the protein level in chronic B-cell proliferative disorders (Delmer et al., 1995) , it should be emphasized that cyclin D2 expression needs to be examined at the protein level to gain insight into its role in oncogenesis of these hematological malignancies. Importantly, the PI3K pathway was found to play a crucial role in maintaining the stability of cyclin D2 in these cells (Figure 5b ). The constitutional activation of this pathway may presumably explain the less significant effects of GSK3b inhibitors of cyclin D2 in these cells than in 32Dcl3 cells starved of IL-3. It is also notable that expression of cyclin D2 was rapidly and drastically decreased in response to osmotic stress in these malignant cells (Figure 5c ). Further studies are currently in progress to study the effects of other cellular stresses, particularly those induced by various chemotherapeutic agents through generation of reactive oxygen species and DNA damages, on cyclin D2 expression and stability. As mutations near the C terminus of cyclin D1 has recently been reported in cancers (Benzeno et al., 2006) , future studies are also needed to examine the possible genetic alterations around Thr280 of cyclin D2 that may interfere with the post-translational regulation mechanisms in hematopoietic malignancies.
Materials and methods

Cells and reagents
Murine IL-3-dependent 32Dcl3 cells were kindly provided by Dr Masakazu Hattori (Kyoto University, Kyoto, Japan) and cultured in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS) and 10% WEHI conditioned medium as the source of IL-3. 32Dcl3 cells and its transfectants growing exponentially in medium containing IL-3 were used for the experiments demonstrated unless otherwise described. Primary leukemic blasts were isolated from patients with AML or ALL, and primary myeloma cells were isolated from pleural effusion of a MM patient. Informed consent was provided according to the Declaration of Helsinki, and the study was approved by the ethical committee of Tokyo Medical and Dental University. Mononuclear cells were isolated by centrifugation through Ficoll-Hypaque, washed in RPMI 1640 medium supplemented with 10% FCS and cryopreserved. The percentages of blasts or myeloma cells in the samples determined morphologically were more than 90%.
Recombinant murine IL-3 was purchased from PeproTech (Rocky Hill, NJ, USA). SB203580, SB216763, LY294002 and Jak-I were purchased from Calbiochem (San Diego, CA, USA). CHX, MG132 and G418 were purchased from SigmaAldrich (St Louis, MO, USA). PD98059 was purchased from Wako chemicals (Osaka, Japan).
Antibodies against cyclin D2 (M-20), a-tubulin (B-7), ubiquitin (P4D1) and GST (B-14) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against p38, phospho-p38 (Thr180/Tyr182), GSK3-b, phospho-GSK3 a/b (Ser21/9), phospho-Akt (Ser473), phosphocyclin D1 (Thr286) and phospho-Erk (Thr202/Tyr204) were purchased from Cell Signaling (Beverly, MA, USA). Anti-FLAG antibody (M2) was purchased from Sigma-Aldrich.
Immunoprecipitation and western blot analysis
For immunoprecipitation experiments, cells were lysed in a lysis buffer containing 1% Triton X-100, 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride and 10 mg/ml each of aprotinin and leupeptin. Cell lysates were subjected to immunoprecipitation and immunoblotting as described previously (Chin et al., 1998) . For immunoblot analysis of total cell lysates, samples were prepared by mixing an aliquot of cell lysates with an equal volume of 2 Â Laemmli's sample buffer and heating at 1001C for 5 min. The results shown, including those using primary cells, are representative of experiments repeated at least twice.
Expression plasmids and transfection
Expression plasmids for human cyclin D2 were constructed by using a reverse transcription-PCR product obtained from peripheral mononuclear cell mRNA into the pcDNA3 and pcDNA4/HisMaxA vectors. The 887-bp fragment obtained using an upstream primer (5 0 -GAAGATCTTCA TGGAGCTGCTGCCACGA-3 0 ) and a downstream primer (5 0 -CCGCTCGAGATCCTCACAGGTCGATATC-3 0 ) was digested with BglII and XhoI, whose recognition sites were added at the 5 0 ends of the primers, and subcloned between the BamHI and XhoI sites into the pcDNA3 and pcDNA4-HismaxA, to generate pcDNA3-cyclin D2 and pcDNAHismax-cyclin D2, respectively. The expression product of the latter plasmid possesses the N-terminal peptide containing the Xpress epitope and the polyhistidine tag, which adds approximately 3.4 kDa to the size of cyclin D2. The expression plasmid pcDNA-cyclin D2-T280A or pcDNA-Hismax-cyclin D2-T280A, which expresses a cyclin D2 mutant with substitution of Thr280 with Ala, was generated by PCR-mediated mutagenesis. The coding regions of all the expression plasmids were validated by DNA sequencing. An expression plasmid for Flag-tagged p38a, pCMV-Flag-p38, was kindly provided by Dr Roger J Davis. An expression plasmid for constitutively activated Akt, pUSE-myr-Akt1, was purchased from Upstate Biotechnology (Lake placid, NY, USA.) Transfection Transfection for stable expression was performed essentially as described previously (Miura et al., 1993) . In brief, 32Dcl3 cells were transfected with pcDNA-cyclin D2 or pcDNA-cyclin D2-T280A by electroporation at 960 mF and 280 V using a Gene Pulser apparatus (Bio-Rad, Hercules, CA, USA), followed by selection in medium containing G418. Clones were isolated by limiting dilution and examined for the expression of cyclin D2 or its mutant. The clone that expresses the highest level of cyclin D2 or cyclin D2-T280A was designated 32D/cyclin D2-Wt or 32D/cyclin D2-T280A, respectively, and used for subsequent studies.
For transient expression in 32Dcl3 cells, 1 Â 10 7 cells were electroporated at 960 mF and 300 V with indicated plasmids. After 16-24 h after transfection, cells were examined as described.
In vitro kinase assays
In vitro kinase assays with recombinant GSK3b or p38 were performed using GST-cyclin D2 fusion proteins as substrates. To construct bacterial expression plasmids for GST-cyclin D2 fusion proteins, the HindIII-XhoI fragment of pcDNA-cyclin D2 or pcDNA-cyclin D2-T280A coding for amino acids 245-289 of wild-type cyclin D2 or the T280A mutant, respectively, was subcloned into pGEX-4T1. The GST-fusion proteins were synthesized by Escherichia coli and prepared as described previously (Chin et al., 1998) . For in vitro kinase reactions, 0.1 mg of GST or GST-fusion protein with wild-type or T280A mutant cyclin D2 was incubated for 20 min at 301C with recombinant p38 (Mal-E-fusion protein; Upstate Biotechnology) or GSK3b (GST-fusion protein, Upstate Biotechnology) in buffer containing 25 mM HEPES (pH 7.4), 10 mM MgCl 2 , 50 mM cold ATP and 0.1 mCi/ml [g-32 P]ATP. Reaction products were then mixed with an equal volume of 2 Â Laemmli's sample buffer and heated at 1001C for 5 min. Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrotransferred to Immobilon P membranes (Millipore, Bedford, MA, USA). Membranes were then exposed to X-ray films and subsequently subjected to immunoblot analysis.
